- Home
- NUW vs IMRX Comparison
NUW vs IMRX Comparison
Compare NUW & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUW
- IMRX
- Stock Information
- Founded
- NUW 2008
- IMRX 2008
- Country
- NUW United States
- IMRX United States
- Employees
- NUW N/A
- IMRX N/A
- Industry
- NUW Investment Managers
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- NUW Finance
- IMRX Health Care
- Exchange
- NUW Nasdaq
- IMRX Nasdaq
- Market Cap
- NUW 252.2M
- IMRX 232.9M
- IPO Year
- NUW N/A
- IMRX 2021
- Fundamental
- Price
- NUW $14.26
- IMRX $6.18
- Analyst Decision
- NUW
- IMRX Strong Buy
- Analyst Count
- NUW 0
- IMRX 4
- Target Price
- NUW N/A
- IMRX $17.75
- AVG Volume (30 Days)
- NUW 45.3K
- IMRX 3.5M
- Earning Date
- NUW 01-01-0001
- IMRX 11-12-2025
- Dividend Yield
- NUW 3.66%
- IMRX N/A
- EPS Growth
- NUW N/A
- IMRX N/A
- EPS
- NUW N/A
- IMRX N/A
- Revenue
- NUW N/A
- IMRX N/A
- Revenue This Year
- NUW N/A
- IMRX N/A
- Revenue Next Year
- NUW N/A
- IMRX N/A
- P/E Ratio
- NUW N/A
- IMRX N/A
- Revenue Growth
- NUW N/A
- IMRX N/A
- 52 Week Low
- NUW $12.45
- IMRX $1.10
- 52 Week High
- NUW $14.44
- IMRX $10.08
- Technical
- Relative Strength Index (RSI)
- NUW 70.31
- IMRX 46.69
- Support Level
- NUW $13.97
- IMRX $6.02
- Resistance Level
- NUW $14.25
- IMRX $9.54
- Average True Range (ATR)
- NUW 0.10
- IMRX 0.96
- MACD
- NUW 0.01
- IMRX -0.37
- Stochastic Oscillator
- NUW 92.22
- IMRX 3.57
About NUW Nuveen AMT-Free Municipal Value Fund
Nuveen AMT-Free Municipal Value Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations. The fund predominantly invests in long-term municipal bonds, corporate bonds, short-term municipal bonds, and other assets.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.